Long-term effects of antihypertensive drug on the risk of new-onset diabetes in elderly Taiwanese hypertensives

International Heart Journal

Volumn 49, Issue 2, 2008, Pages 205-211

  Liou, Yi Sheng ^a   Ma, Tsochiang ^b   Tien, Liyun ^c   Chien, Chingwen ^d   Chou, Pesus ^d   Jong, Gwo Ping ^e  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c Bureau of National Health Insurance Taiwan   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Antihypertensive drugs; Elderly; Hypertension; New onset diabetes

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GERIATRIC PATIENT; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; TAIWAN; CHEMICALLY INDUCED DISORDER; ONSET AGE; RETROSPECTIVE STUDY; TIME;

ADRENERGIC BETA-ANTAGONISTS; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS; DIURETICS; FEMALE; HUMANS; HYPERTENSION; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TIME FACTORS;

EID: 45549084643     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.49.205     Document Type: Article

References (22)

1. Demir I, Ermis C, Altunbas H, Balci MK. Scrum HbAlc levels and exercise capacity in diabetic patients. Jpn Heart J 2001; 42: 607-16.
2. Katayama T, Nakashima H, Takagi C, et al. Clinical outcomes and left ventricular function in diabetic patients with acute myocardial infarction treated. by primary coronary angioplasty. Int Heart J 2005; 46: 607-18.
3. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-12.
4. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
5. Elliott WJ. Differential effects of antihypertensive drugs on new-onset diabetes? Curr Hypertens Rep 2005; 7: 249-56.
6. Julius S, Kjeldsen. SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
7. Rajala U, Qiao Q, Laakso M, Keinänen-Kiukaanniemi S. Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Res Clin Pract 2000; 50: 231-9.
8. Morales PA, Mitchell BD, Valdez RA, Hazuda HP, Stern MP, Haffner SM. Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects: The San Antonio Heart Study. Diabetes 1993; 42: 154-61.
9. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006; 29: 1065-70.
10. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Mej 2003; 348: 583-92.
11. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65.
12. Mancia, G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10.
13. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004; 27: 247-55.
14. Padwal R, Mamdani M, Alter DA, et al. Anthypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care 2004; 27: 2458-63.
15. Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 2006; 6: 796-806.
16. Andraws F, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007; 99: 1006-12.
17. McCall KL, Craddock D, Edwards K. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis. Pharmacotherapy 2006; 26: 1297-306. (Rewiew)
18. Lithell HO. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertens 1996; 9: 150S-4.
19. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J; The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004; 47: 1519-27.
20. Hansson L, Lindhohn LH, Niskanen L, et al. Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611-6.
21. Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107:1291-6.
22. Aguilar D, Solomon SD. ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging theme. Drugs 2006; 66: 1169-77.